Media coverage about Galena Biopharma (NASDAQ:GALE) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galena Biopharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.1967039817191 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s scoring:
- Technical Picture: Shares of Galena Biopharma, Inc. (GALE) are worth at $0.41 – Wall Street Morning (wallstreetmorning.com)
- Healthcare Stock is Neither buy nor sell: Galena Biopharma, Inc. (GALE) – Street Observer (press release) (streetobserver.com)
- Galena Biopharma, Inc. (NASDAQ:GALE) Experiences Heavier than Average Trading Volume – First News 24 (firstnewspaper24.com)
- Up to Date Stock in Review: CenturyLink, Inc. (NYSE:CTL), Galena Biopharma, Inc. (NASDAQ:GALE), Marathon … – Market Breaking Point (press release) (journalfinance.net)
Separately, Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a research report on Wednesday, August 9th.
Shares of Galena Biopharma (NASDAQ:GALE) traded up 4.9269% on Friday, reaching $0.4089. 2,612,507 shares of the company were exchanged. The company’s 50-day moving average is $0.36 and its 200-day moving average is $0.51. Galena Biopharma has a 52 week low of $0.16 and a 52 week high of $4.75. The company’s market capitalization is $15.70 million.
Galena Biopharma (NASDAQ:GALE) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). During the same period in the prior year, the company posted $0.05 EPS. On average, equities analysts expect that Galena Biopharma will post ($0.59) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://transcriptdaily.com/2017/10/08/galena-biopharma-gale-given-daily-media-sentiment-rating-of-0-14.html.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.